

Amphastar Pharmaceuticals, Inc.
 Form 4
 June 09, 2015

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549

OMB APPROVAL
 OMB Number: 3235-0287
 Expires: January 31, 2015
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 Zhang Jack Y.

2. Issuer Name and Ticker or Trading Symbol
 Amphastar Pharmaceuticals, Inc.
 [AMPH]

5. Relationship of Reporting Person(s) to Issuer
 (Check all applicable)
 Director 10% Owner
 Officer (give title below) Other (specify below)
 CEO & Chief Science Officer

(Last) (First) (Middle)

C/O AMPHASTAR
 PHARMACEUTICALS,
 INC., 11570 6TH STREET

3. Date of Earliest Transaction
 (Month/Day/Year)
 03/27/2015

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

RANCHO
 CUCAMONGA, CA 91730

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V Amount or (D) Price			
Common Stock	03/27/2015		F	20,877 (1) D \$ 15.43	911,636	D	
Common Stock	06/05/2015		M	48,980 A \$ 12.97	960,616	D	
Common Stock	06/05/2015		S(2)	44,149 D \$ 16.4642 (3)	916,467	D	
Common Stock	06/08/2015		M	30,066 A \$ 12.97	946,533	D	

Edgar Filing: Amphastar Pharmaceuticals, Inc. - Form 4

Common Stock	06/08/2015	<u>S</u> (2)	27,020	D	\$ 16.614 (4)	919,513	D	
Common Stock	06/09/2015	M	28,324	A	\$ 12.97	947,837	D	
Common Stock	06/09/2015	<u>S</u> (2)	25,700	D	\$ 16.2356 (5)	922,137	D	
Common Stock	03/27/2015	F	8,641 (1)	D	\$ 15.43	661,666	I	See footnote (6)
Common Stock	06/05/2015	M	50,162	A	\$ 12.97	711,828	I	See footnote (6)
Common Stock	06/05/2015	<u>S</u> (2)	43,989	D	\$ 16.4657 (7)	667,839	I	See footnote (6)
Common Stock	06/08/2015	M	30,152	A	\$ 12.97	697,991	I	See footnote (6)
Common Stock	06/08/2015	<u>S</u> (2)	27,100	D	\$ 16.6087 (8)	670,891	I	See footnote (6)
Common Stock	06/09/2015	M	28,433	A	\$ 12.97	699,324	I	See footnote (6)
Common Stock	06/09/2015	<u>S</u> (2)	25,800	D	\$ 16.1229 (9)	673,524	I	See footnote (6)
Common Stock						7,631,594	I	See footnote (10)
Common Stock						5,000	I	See footnote (11)
Common Stock						200,000	I	See footnote (12)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Edgar Filing: Amphastar Pharmaceuticals, Inc. - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)
				Code	V (A) (D)	Date Exercisable Expiration Date	Title Amount or Number of Shares
Employee Stock Option (right to buy)	\$ 12.97	06/05/2015		M	48,980	<u>(13)</u> 09/28/2015	Common Stock 48,980
Employee Stock Option (right to buy)	\$ 12.97	06/08/2015		M	30,066	<u>(13)</u> 09/28/2015	Common Stock 30,066
Employee Stock Option (right to buy)	\$ 12.97	06/09/2015		M	28,324	<u>(13)</u> 09/28/2015	Common Stock 28,324
Employee Stock Option (right to buy)	\$ 12.97	06/05/2015		M	50,162	<u>(13)</u> 09/28/2015	Common Stock 50,162
Employee Stock Option (right to buy)	\$ 12.97	06/08/2015		M	30,152	<u>(13)</u> 09/28/2015	Common Stock 30,152
Employee Stock Option (right to buy)	\$ 12.97	06/09/2015		M	28,433	<u>(13)</u> 09/28/2015	Common Stock 28,433

Reporting Owners

Reporting Owner Name / Address

Relationships

Reporting Owners

Edgar Filing: Amphastar Pharmaceuticals, Inc. - Form 4

	Director	10% Owner	Officer	Other
Zhang Jack Y. C/O AMPHASTAR PHARMACEUTICALS, INC. 11570 6TH STREET RANCHO CUCAMONGA, CA 91730	X	X	CEO & Chief Science Officer	
Luo Mary Z. C/O AMPHASTAR PHARMACEUTICALS, INC. 11570 6TH STREET RANCHO CUCAMONGA, CA 91730	X	X	COO, Chief Scientist, Chairman	

Signatures

/s/ Ken Stupak, by power of attorney for Jack Y. Zhang 06/09/2015

**Signature of Reporting Person Date

/s/ Ken Stupak, by power of attorney for Mary Z. Luo 06/09/2015

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
 - ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The reported securities were withheld to satisfy the Reporting Person's tax liability in connection with the vesting of deferred stock units (DSUs).
 - (2) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the each of the reporting persons on December 16, 2014.
 - (3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$16.28 to \$16.5015, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3), (4), (5), (7), (8) and (9) to this Form 4.
 - (4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$16.41 to \$16.85, inclusive.
 - (5) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$16.50 to \$16.595, inclusive.
 - (6) The securities are held of record by Mary Z. Luo. The reporting persons are husband and wife.
 - (7) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$16.28 to \$16.52, inclusive.
 - (8) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$16.41 to \$16.825, inclusive.
 - (9) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$16.00 to \$16.595, inclusive.
 - (10) The shares are held of record by Applied Physics & Chemistry Laboratories, Inc., of which the reporting persons are the sole owners.
 - (11) The shares are held of record in an account for the benefit of the reporting persons' son. The reporting persons disclaims beneficial ownership of these shares, and the inclusion of these shares in this report should not be deemed an admission of beneficial ownership of any such shares for purposes of Section 16, or for any other purpose.
 - (12) The shares are held of record by a trust for the benefit of the reporting persons' son. The reporting persons disclaims beneficial ownership of these shares, and the inclusion of these shares in this report should not be deemed an admission of beneficial ownership of any such shares for purposes of Section 16, or for any other purpose.

Edgar Filing: Amphastar Pharmaceuticals, Inc. - Form 4

(13) Shares subject to the option are fully vested and immediately exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.